Fig. 5.
Effect of rapamycin treatment on the expression of proteins regulating late G1 progression and cdk2 kinase activity.
(A) Immunoblots were performed with mAb against cyclin E, cyclin A, and cdk2 in activated B-CLL cells with or without rapamycin (Rap) at 50 ng/mL. (B) The result of an in vitro kinase assay using histone H1 as a substrate for cdk2 immunoprecipitates of activated B-CLL cells cultured with or without rapamycin. Each experiment was repeated twice with similar results.